Growth & profitability
- Revenue has grown 145.9% per year over the past 5 years.
Financial health
- Operating income covered interest expense -2287.8× in the latest year.
STOK Financials Stoke Therapeutics, Inc.
8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $184M | -$7M | 0.0% | -11.2% | -2.0% | -1.6% | $45M | — | $84M |
| 2024 | $37M | -$89M | 0.0% | -277.3% | -38.9% | -32.8% | -$87M | — | $128M |
| 2023 | $9M | -$105M | 0.0% | -1307.2% | -65.6% | -45.9% | -$83M | — | $191M |
| 2022 | $12M | -$101M | 0.0% | -841.2% | -54.7% | -39.5% | -$36M | — | $114M |
| 2021 | — | -$86M | — | — | -39.4% | -35.9% | -$68M | — | $145M |
| 2020 | — | -$52M | — | — | -18.3% | -17.5% | -$43M | — | $287M |
| 2019 | — | -$32M | — | — | -14.4% | -14.1% | -$33M | — | $222M |
| 2018 | — | -$13M | — | — | -11.9% | -11.6% | -$12M | — | $105M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $9M | -$62M | 0.0% | -701.7% | -17.8% | -15.6% | -$59M | — | $110M |
| Mar '26 | $6M | -$50M | 0.0% | -857.6% | -12.7% | -11.3% | -$61M | — | $156M |
| Dec '25 | $1M | -$58M | 0.0% | -4382.2% | -16.4% | -13.8% | -$31M | — | $84M |
| Sep '25 | $11M | -$38M | 0.0% | -405.3% | -12.4% | -10.6% | -$30M | — | $83M |
| Jun '25 | $14M | -$23M | 0.0% | -197.6% | -7.0% | -6.1% | -$26M | — | $101M |
| Mar '25 | $159M | $113M | 0.0% | 70.2% | 32.2% | 27.7% | $132M | — | $275M |
| Dec '24 | $23M | -$10M | 0.0% | -60.4% | -4.6% | -3.9% | -$23M | — | $128M |
| Sep '24 | $5M | -$26M | 0.0% | -613.1% | -11.4% | -9.0% | -$22M | — | $150M |
| Jun '24 | $5M | -$26M | 0.0% | -607.4% | -10.6% | -8.3% | -$18M | — | $193M |
| Mar '24 | $4M | -$26M | 0.0% | -673.0% | -18.8% | -12.9% | -$25M | — | $179M |
| Dec '23 | $3M | -$27M | 0.0% | -1055.9% | -16.9% | -11.8% | -$21M | — | $191M |
| Sep '23 | $3M | -$25M | 0.0% | -823.3% | -14.2% | -10.2% | -$18M | — | $190M |
| Jun '23 | -$2M | -$31M | 0.0% | 1340.7% | -16.1% | -11.9% | -$23M | — | $192M |
| Mar '23 | $5M | -$23M | 0.0% | -479.2% | -10.5% | -8.0% | -$22M | — | $190M |
| Dec '22 | $3M | -$26M | 0.0% | -831.6% | -13.9% | -10.0% | -$23M | — | $114M |
| Sep '22 | $3M | -$26M | 0.0% | -934.5% | -12.8% | -9.4% | -$24M | — | $113M |
| Jun '22 | $3M | -$25M | 0.0% | -781.1% | -11.0% | -8.2% | -$21M | — | $68M |
| Mar '22 | $3M | -$25M | 0.0% | -826.5% | -10.3% | -7.8% | $32M | — | $84M |
| Dec '21 | — | -$24M | — | — | -11.2% | -10.2% | -$16M | — | $145M |
| Sep '21 | — | -$23M | — | — | -9.5% | -8.9% | -$15M | — | $149M |
Valuation over time
How the market has priced STOK against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 43.3× (Mar '23) to 10.5× (Sep '26).
P/S
Frequently asked questions
Is STOK growing its revenue and profit?
Over the past 5 years, Stoke Therapeutics, Inc.'s revenue has grown 145.9% per year. These are computed facts, not advice.
How much debt does STOK have?
As of FY2025, Stoke Therapeutics, Inc. reported — of total debt against $84M of cash; operating income covered interest expense -2287.8×.
What is STOK's profit margin?
In FY2025, gross margin was —, operating margin -11.2%, and net margin -3.7%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.